The purpose of the study is to describe patient characteristics and drug usage among patients that are prescribed ticagrelor for the first time and to compare them with patients who are prescribed clopidogrel and prasugrel for the first time. A further purpose is to ascertain and estimate the crude incidence rate of bleeding, arrhythmias, heart failure, acute renal failure, acute liver failure, dyspnoea and gout among new users in the three cohorts of ticagrelor, clopidogrel and prasugrel.
Study Type
OBSERVATIONAL
Enrollment
7,200
First time users of ticagrelor, clopidogrel and prasugrel, respectively
Research Site
Stockholm, Sweden
Drug utilization: Description of patient characteristics and drug usage
Time frame: Up to one year after entry into study cohort
Follow-up of safety outcomes: First occurrence of bleeding, arrhythmias, heart failure, acute renal failure, acute liver failure, dyspnoea and gout
Time frame: Up to one year after entry into study cohort.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.